{"product_id":"interventional-oncology-for-breast-cancer-a-patients-guide-to-minimally-invasive-treatments","title":"Interventional Oncology for Breast Cancer: A Patient's Guide to Minimally Invasive Treatments","description":"\u003cp\u003eBreast cancer is the most common cancer and one of the most important causes of death among women worldwide, with a lifetime risk of about 10%. While surgery has long been the standard treatment, a field called interventional oncology (IO) is increasingly offering less invasive alternatives using image-guided techniques such as cryoablation (extreme cold), radiofrequency ablation (heat), and liver-directed arterial therapies. This review article explains how these minimally invasive approaches are being used to treat both primary breast tumors and breast cancer liver metastases, with promising success rates, excellent safety profiles, and superior cosmetic outcomes for well-selected patients. For those who cannot have surgery or prefer to avoid it, these techniques represent an important and growing treatment option that requires careful discussion within a multidisciplinary team.\u003c\/p\u003e\n\n\u003ch1\u003eInterventional Oncology for Breast Cancer: A Patient's Guide to Minimally Invasive Treatments\u003c\/h1\u003e\n\n\u003ch2\u003eTable of Contents\u003c\/h2\u003e\n\u003cul\u003e\n\u003cli\u003e\u003ca href=\"#ddn-key-points\"\u003eKey Points\u003c\/a\u003e\u003c\/li\u003e\n\n  \u003cli\u003e\u003ca href=\"#introduction\"\u003eIntroduction: What This Article Covers\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#background\"\u003eBackground: Breast Cancer and the Shift Toward Gentler Treatments\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#percutaneous\"\u003ePercutaneous Treatments for Early-Stage Breast Cancer\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#cryoablation\"\u003eCryoablation: Freezing the Tumor\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#rfa\"\u003eRadiofrequency Ablation (RFA): Heating the Tumor\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#mwa\"\u003eMicrowave Ablation (MWA): Faster, Hotter, and More Powerful\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#laser\"\u003eLaser Ablation: Using Light to Destroy Cancer\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#hifu\"\u003eHigh-Intensity Focused Ultrasound (HIFU): No Needles Required\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#bclm\"\u003eWhen Breast Cancer Spreads to the Liver (BCLM)\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#liver-ablation\"\u003ePercutaneous Ablation for Liver Metastases\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#intra-arterial\"\u003eIntra-Arterial Therapies: Delivering Treatment Through the Blood Supply\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#tace\"\u003eTransarterial Chemoembolization (TACE)\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#tare\"\u003eTransarterial Radioembolization (TARE)\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#clinical-implications\"\u003eClinical Implications: What This Means for Patients\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#limitations\"\u003eLimitations: What the Research Can't Yet Tell Us\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#recommendations\"\u003eRecommendations for Patients\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#ddn-faq\"\u003eFrequently Asked Questions\u003c\/a\u003e\u003c\/li\u003e\n\u003cli\u003e\u003ca href=\"#source\"\u003eSource Information\u003c\/a\u003e\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003c!-- ddn:keypoints:start --\u003e\n\u003ch2 id=\"ddn-key-points\"\u003eKey Points\u003c\/h2\u003e\n\u003cul\u003e\n\u003cli\u003eInterventional oncology uses image-guided techniques like cryoablation, radiofrequency, microwave, laser, and high-intensity focused ultrasound to treat breast tumors without surgery.\u003c\/li\u003e\n\u003cli\u003eIn a meta-analysis of 397 breast cancers up to 2 cm, cryoablation achieved complete ablation in 85% of cases and had the fewest complications among thermal ablation methods.\u003c\/li\u003e\n\u003cli\u003eFor breast cancer liver metastases, percutaneous ablation can achieve local control with a mortality of 0.15%, compared with up to 5.8% for surgical resection.\u003c\/li\u003e\n\u003cli\u003eIntra-arterial therapies such as TACE and TARE may provide survival benefits for liver metastases, especially in patients who respond to treatment.\u003c\/li\u003e\n\u003cli\u003eThere is no high-level evidence or specific guidelines for local therapies in metastatic breast cancer; decisions should be made by a multidisciplinary team board.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c!-- ddn:keypoints:end --\u003e\n\n\n\u003ch2 id=\"introduction\"\u003eIntroduction: What This Article Covers\u003c\/h2\u003e\n\u003cp\u003eThis article is based on a peer-reviewed medical review written by Dr. Franco Orsi at the European Institute of Oncology in Milan, Italy, published in the \u003cem\u003eJournal of Medical Imaging and Radiation Oncology\u003c\/em\u003e in 2023. It explores the growing role of interventional oncology (IO) in breast cancer treatment.\u003c\/p\u003e\n\u003cp\u003eInterventional oncology uses minimally invasive, image-guided procedures to diagnose and treat cancer. Instead of making large incisions, doctors use needles, probes, or catheters guided by imaging tools like ultrasound, CT, or MRI to target tumors directly. The review covers two main areas: treating the primary breast tumor itself without surgery, and treating breast cancer that has spread to the liver (breast cancer liver metastases, or BCLM).\u003c\/p\u003e\n\n\u003ch2 id=\"background\"\u003eBackground: Breast Cancer and the Shift Toward Gentler Treatments\u003c\/h2\u003e\n\u003cp\u003eBreast cancer is the most common cancer worldwide among women and one of the most important causes of death in this group. The incidence varies across European countries, but overall, the lifetime risk of developing breast cancer is about 10% for women. Over the past few decades, survival has improved significantly, thanks largely to breast screening programs available in most European countries and easier access to diagnostic services for women with breast symptoms. These advances allow breast cancer to be detected at earlier stages and treated more promptly.\u003c\/p\u003e\n\u003cp\u003eTreatment of breast cancer itself has evolved dramatically. Surgery has moved from radical mastectomy (complete removal of the breast) to breast-conserving surgery, which removes only the tumor and a small margin of surrounding tissue. This shift was made possible by earlier imaging detection, which allows less radical surgery, and by advances in biology and molecular classification of different breast cancer subtypes. Personalized cancer care and new standardization of surgical margins in breast-conserving surgery are creating both opportunities and challenges.\u003c\/p\u003e\n\u003cp\u003eDespite these improvements, metastatic disease remains a serious problem. Approximately 3.5–7% of breast cancer patients initially present with distant metastases (meaning the cancer has already spread at the time of diagnosis, classified as Stage IV). Additionally, nearly 30–40% of women initially diagnosed with early-stage disease will eventually develop metastatic lesions, months or even years later.\u003c\/p\u003e\n\u003cp\u003eThe most common sites where breast cancer spreads are:\u003c\/p\u003e\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003eBone\u003c\/strong\u003e (51% of metastatic cases)\u003c\/li\u003e\n  \u003cli\u003e\u003cstrong\u003eLung\u003c\/strong\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003cstrong\u003eBrain\u003c\/strong\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003cstrong\u003eLiver\u003c\/strong\u003e\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eFor Stage IV breast cancer, systemic therapy is the standard of care. This includes chemotherapy, endocrine therapy (hormone therapy), or HER2-targeted therapy, depending on whether the tumor has oestrogen\/progesterone receptors and HER2 status. Even with these treatments, the median overall survival for Stage IV patients is 2–3 years, and the 5-year survival rate is only about 25%.\u003c\/p\u003e\n\u003cp\u003eLocal treatments — such as surgery, radiation therapy, and more recently interventional oncology procedures — are sometimes added to systemic therapy. Recent evidence shows that these local approaches can benefit patients with oligo-metastatic disease (a limited number of metastases) or oligo-progressive liver disease, improving survival compared with systemic treatment alone. Local treatments can also help relieve symptoms, which improves patients' treatment adherence, satisfaction, and overall well-being.\u003c\/p\u003e\n\u003cp\u003eIt is important to note that there is currently no high-level evidence confirming the effectiveness of local therapies in metastatic breast cancer, and no specific guidelines are available. However, within the \"Recommendation Statements\" from the European School of Oncology (ESO)–MBC Task Force, local treatment of a \"solitary metastatic lesion\" is an accepted indication. The Task Force also emphasizes the need for a multidisciplinary team board (MDTB) discussion to define a tailored treatment plan for each metastatic breast cancer patient. For these reasons, a breast cancer treatment center must have access to interventional oncology expertise.\u003c\/p\u003e\n\n\u003ch2 id=\"percutaneous\"\u003ePercutaneous Treatments for Early-Stage Breast Cancer\u003c\/h2\u003e\n\u003cp\u003eWomen with newly diagnosed breast cancer typically undergo breast-conserving surgery, the standard treatment for early-stage disease. This procedure involves local tumor excision with clear margins plus sentinel lymph node biopsy for invasive cancers. For both invasive and in situ (non-invasive) breast carcinoma, the status of the surgical margins is one of the main factors affecting the risk of local recurrence.\u003c\/p\u003e\n\u003cp\u003eCurrent guidelines support a negative margin defined as \"no ink on tumor\" to minimize local recurrence risk in invasive breast cancer. For women with ductal carcinoma in situ (DCIS) treated with lumpectomy plus radiation therapy, a minimum margin of 2 mm is required, and larger margins do not provide added benefit.\u003c\/p\u003e\n\u003cp\u003eAlthough surgery remains the standard of care, some patients cannot undergo resection due to:\u003c\/p\u003e\n\u003cul\u003e\n  \u003cli\u003eComorbidities (other health conditions that make surgery risky)\u003c\/li\u003e\n  \u003cli\u003eAdvanced age\u003c\/li\u003e\n  \u003cli\u003ePatient refusal\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eThese patients may be considered for percutaneous ablation, a procedure in which a needle or probe is inserted through the skin directly into the tumor. Percutaneous thermal ablation (TA) techniques include cryoablation (CA), radiofrequency ablation (RFA), laser ablation (LA), microwave ablation (MWA), and high-intensity focused ultrasound (HIFU).\u003c\/p\u003e\n\u003cp\u003eThe advantages of percutaneous therapy are significant:\u003c\/p\u003e\n\u003cul\u003e\n  \u003cli\u003eOutpatient treatment (no hospital stay required)\u003c\/li\u003e\n  \u003cli\u003eLow rate of complications\u003c\/li\u003e\n  \u003cli\u003eMinimal scarring\u003c\/li\u003e\n  \u003cli\u003eRapid recovery\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eThe main drawback is that the tumor is not removed, so it cannot be examined under a microscope afterward. Because core biopsies cannot assess whether tumor-free margins have been achieved, doctors must oversize the ablation area to avoid recurrence. A margin of 5 mm beyond the visible tumor is considered necessary for thermal ablation. Heat-based techniques can be painful and generally require local anesthesia plus intravenous sedation.\u003c\/p\u003e\n\n\u003ch2 id=\"cryoablation\"\u003eCryoablation: Freezing the Tumor\u003c\/h2\u003e\n\u003cp\u003eCryoablation is an emerging therapeutic technique that uses extremely low temperatures to destroy cancer cells. Under image guidance — most commonly ultrasound, which easily visualizes the \"ice ball\" forming during the procedure — the doctor places a small cryoprobe through the skin into the tumor. One of the key advantages of cryoablation is the ability to clearly see the area being treated in real time on ultrasound images, which helps ensure the entire tumor is frozen while minimizing damage to surrounding healthy tissue.\u003c\/p\u003e\n\u003cp\u003eThe technique was first described in 1985 and, thanks to recent technical improvements, can now be performed using small, easy-to-handle cryoprobes powered by argon gas or liquid nitrogen.\u003c\/p\u003e\n\u003cp\u003eCryoablation offers several important benefits compared with heat-based techniques:\u003c\/p\u003e\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003eIt is essentially painless\u003c\/strong\u003e — cold temperatures have an analgesic (pain-relieving) effect, unlike heat-based methods\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eIt can be performed safely without sedation\u003c\/strong\u003e — only local anesthesia is needed for the probe insertion\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eIt offers better cosmetic outcomes\u003c\/strong\u003e — minimal scarring\u003c\/li\u003e\n  \u003cli\u003e\u003cstrong\u003eIt has a low complication rate\u003c\/strong\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003cstrong\u003eIt is low cost\u003c\/strong\u003e\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eA recent meta-analysis studied 397 breast cancers up to 2 cm in size treated with cryoablation and reported complete ablation in 339 cases — a success rate of 85% (95% confidence interval 82–89%). The analysis also found that cryoablation is the thermal ablation technique with the fewest associated complications compared to heat-based methods.\u003c\/p\u003e\n\u003cp\u003eTwo ongoing clinical trials are currently studying cryoablation as a replacement for surgery:\u003c\/p\u003e\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003eICE3\u003c\/strong\u003e (Cryoablation of Low Risk Small Breast Cancer) — A prospective study in women aged 50 or over with early-stage hormone receptor-positive, HER2-negative breast cancer. The interim analysis reported an ipsilateral breast tumor recurrence (IBTR) rate of only 2% at a mean follow-up of 34.83 months after cryoablation without surgery.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eFROST\u003c\/strong\u003e (Freezing instead of Removal Of Small Tumours) — Studying cryoablation without surgery and its impact on local or distant recurrence at 5 years.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eThese trials will help determine whether cryoablation can be a definitive treatment for small, low-risk breast cancers in appropriate patients.\u003c\/p\u003e\n\n\u003ch2 id=\"rfa\"\u003eRadiofrequency Ablation (RFA): Heating the Tumor\u003c\/h2\u003e\n\u003cp\u003eRadiofrequency ablation is one of the most extensively studied thermal ablation techniques for breast cancer. In a meta-analysis of all thermal ablation techniques for breast cancer, more than half of the lesions in 1,156 patients were ablated using RFA — specifically, 577 lesions (50%).\u003c\/p\u003e\n\u003cp\u003eRFA works by passing an alternating electrical current between the needle tip placed in the tumor and a skin electrode pad. The friction of ions adjacent to the needle converts electrical energy into heat, which destroys the cancer cells.\u003c\/p\u003e\n\u003cp\u003eSeveral studies have shown promising rates of complete ablation with an excellent safety profile. Most patients in these studies underwent surgical excision after RFA, and pathological examination confirmed complete ablation of the target lesion.\u003c\/p\u003e\n\u003cp\u003eA randomized trial compared breast cancer treatment using RFA followed by lumpectomy versus lumpectomy alone (considered the standard treatment). The study compared margin status, cosmetic results, adverse events, and local recurrences between the two groups. The results showed:\u003c\/p\u003e\n\u003cul\u003e\n  \u003cli\u003eClear tumor margins were \u003cstrong\u003emore frequent\u003c\/strong\u003e when RFA was used before lumpectomy\u003c\/li\u003e\n  \u003cli\u003eHowever, RFA had a \u003cstrong\u003ehigher complication rate\u003c\/strong\u003e, mainly local breast inflammation and local infection, especially when combined with partial irradiation of the breast\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eIn a prospective study in which patients did not undergo surgical resection after RFA, imaging was the only method used to assess the success of the ablation. Results showed that relapses were delayed — occurring at 30, 48, and 60 months — and were located outside the ablation zone, suggesting that RFA successfully destroyed the targeted tumor tissue.\u003c\/p\u003e\n\n\u003ch2 id=\"mwa\"\u003eMicrowave Ablation (MWA): Faster, Hotter, and More Powerful\u003c\/h2\u003e\n\u003cp\u003eMicrowave ablation was more recently proposed for treating breast tumors. Compared with RFA, MWA offers several technical advantages:\u003c\/p\u003e\n\u003cul\u003e\n  \u003cli\u003eConsistently higher temperatures\u003c\/li\u003e\n  \u003cli\u003eLarger tumor ablation volumes\u003c\/li\u003e\n  \u003cli\u003eFaster treatment times\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eMWA works by generating an oscillating electromagnetic field from an antenna (needle) placed in the tumor. This field induces heat in the adjacent tissue through the kinetic energy of water molecules (dipoles) within the cells, essentially cooking the tumor from the inside out.\u003c\/p\u003e\n\u003cp\u003eAn \"ablate and resect\" study of ultrasound-guided MWA for small breast cancers demonstrated results similar to RFA: complete tumor coagulation was achieved in 95% of cases (36 out of 38 tumors). However, treatments in this study were performed under general anesthesia, and complications included thermal injuries to the skin and the pectoralis major muscle (the chest muscle beneath the breast). These side effects highlight the importance of careful technique and patient selection.\u003c\/p\u003e\n\n\u003ch2 id=\"laser\"\u003eLaser Ablation: Using Light to Destroy Cancer\u003c\/h2\u003e\n\u003cp\u003eLaser ablation destroys tumors by converting light into thermal (heat) energy, which heats and kills the cancer cells. Among thermal ablation techniques, interstitial laser photocoagulation was one of the first to be reported for treating breast tumors, dating back to the 1990s.\u003c\/p\u003e\n\u003cp\u003eAn open-label phase 2 multicentre clinical trial evaluated laser ablation followed by surgical removal of the treated area. The study compared 28-day post-ablation MRI images with the surgical pathology to determine whether any residual tumor remained after ablation. Here are the key results from this trial:\u003c\/p\u003e\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003e61 patients\u003c\/strong\u003e were enrolled in the study\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003e51 patients (84%)\u003c\/strong\u003e had complete tumor ablation confirmed by pathology analysis\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003e4 patients (6.7%)\u003c\/strong\u003e had false-positive MRI results (MRI suggested residual tumor, but none was found)\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003e4 patients (6.7%)\u003c\/strong\u003e had false-negative MRI results (MRI showed no residual tumor, but pathology found some)\u003c\/li\u003e\n  \u003cli\u003eThe overall negative predictive value (NPV) of MRI — meaning the probability that a negative MRI truly means no residual tumor — was \u003cstrong\u003e92.2%\u003c\/strong\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eEven better results were obtained for tumors up to 15 mm in size, where the MRI negative predictive value rose to \u003cstrong\u003e97.7%\u003c\/strong\u003e. Adverse events were minimal, and the majority of patients — 96.6% — reported good to excellent satisfaction 28 days after the procedure.\u003c\/p\u003e\n\u003cp\u003eThis means that for small tumors, MRI is quite reliable at confirming successful ablation, though it is not perfect.\u003c\/p\u003e\n\n\u003ch2 id=\"hifu\"\u003eHigh-Intensity Focused Ultrasound (HIFU): No Needles Required\u003c\/h2\u003e\n\u003cp\u003eHigh-intensity focused ultrasound is unique among the ablation techniques because it requires no needle insertion at all. Instead, focused mechanical ultrasound waves are delivered into the body to a predefined target. The patient lies on their stomach (prone position), and the therapeutic transducer (the device that emits the ultrasound waves) is placed below or to the side of the breast.\u003c\/p\u003e\n\u003cp\u003eHIFU can be guided by either ultrasound (USgHIFU) or magnetic resonance imaging (MRgHIFU). MRI guidance offers advantages because it allows precise treatment planning and real-time temperature monitoring through special thermometry sequences, so the doctor can see exactly how hot the tissue is getting during treatment.\u003c\/p\u003e\n\u003cp\u003eHere is how the technology works: a beam of ultrasound waves is concentrated into a focal point within a small volume of tissue using a spherically curved phased-array transducer. At that focal spot, the absorption of energy creates a highly localized temperature increase, leading to protein coagulation (the proteins in cells clump together and stop functioning) and cell death. The temperature rise depends mainly on how much energy the tissue absorbs, and it can be reduced by attenuation from the tissues the waves must pass through on their way to the target.\u003c\/p\u003e\n\u003cp\u003eMRgHIFU has been tested on breast tumors since the 2000s, but studies are still scarce, with most conducted as pilot feasibility and safety studies. The efficacy results are mixed and variable, with complete tumor ablation success rates ranging from \u003cstrong\u003e20% to 100%\u003c\/strong\u003e across different studies. This wide variation is largely due to differences in MRgHIFU systems, imaging techniques, ablation protocols, and patient selection criteria used in the published studies.\u003c\/p\u003e\n\u003cp\u003eIn one series of breast cancer patients treated with ultrasound-guided HIFU followed by modified radical mastectomy (surgical removal of the breast), complete ablation was demonstrated in \u003cstrong\u003e100% of cases\u003c\/strong\u003e. However, the technology has some important limitations at present:\u003c\/p\u003e\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003eCost\u003c\/strong\u003e — especially for MRI-guided systems\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eLong treatment times\u003c\/strong\u003e — typically 35 to 150 minutes per session\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eRisk of target lesion motion\u003c\/strong\u003e — the tumor may shift during treatment (for example, with breathing), which can affect accuracy\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eThe technology is promising but requires further development before it can be widely adopted.\u003c\/p\u003e\n\n\u003ch2 id=\"bclm\"\u003eWhen Breast Cancer Spreads to the Liver (BCLM)\u003c\/h2\u003e\n\u003cp\u003eBreast cancer liver metastases (BCLM) represent a complex oncological situation in which systemic therapy plays the crucial therapeutic role in improving both the quality and quantity of life. The primary goal of any local therapy in metastatic breast cancer is to achieve local disease control that translates into a clinical benefit — ideally, longer survival or better symptom control.\u003c\/p\u003e\n\u003cp\u003eThe aim of local tumor treatment depends on the stage of the disease and the extent of liver involvement:\u003c\/p\u003e\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003ePatients with extensive extrahepatic disease\u003c\/strong\u003e (cancer spread beyond the liver): Their survival is primarily driven by the overall tumor burden, so it may not be desirable to ablate every single liver metastasis.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003ePatients whose metastatic involvement is confined to the liver\u003c\/strong\u003e: Complete ablation is preferable if it can be achieved safely.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eTwo clinical scenarios where local minimally invasive therapies are increasingly indicated are:\u003c\/p\u003e\n\u003col\u003e\n  \u003cli\u003e\n\u003cstrong\u003eOligo-metastatic disease\u003c\/strong\u003e — defined as the presence of ≤5 metastatic deposits. In this situation, a radical (curative) outcome is reasonably achievable, and percutaneous ablations are mainly indicated.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eOligo-progressive metastatic disease\u003c\/strong\u003e — a newer disease concept with no consensus definition yet. In clinical practice, there is a growing number of metastatic breast cancer patients in whom systemic therapy remains effective long-term, but one or a few deposits stop responding. Rather than changing the systemic treatment (which may be working well elsewhere), treating only the non-responsive lesions locally may allow the effective systemic therapy to continue.\u003c\/li\u003e\n\u003c\/ol\u003e\n\u003cp\u003eLocoregional and local therapies — such as percutaneous ablations and intra-arterial techniques — may only benefit very well-selected patients. According to the very few data available in the literature (mostly from small retrospective studies), a multidisciplinary team board (MDTB) discussion is mandatory for defining the indications for interventional oncology treatments outside of clinical trials. As BCLM is a complex condition with no standard established therapy, the MDTB is considered crucial for planning a personalized treatment strategy.\u003c\/p\u003e\n\u003cp\u003eAmong the available options for local therapy in liver disease, percutaneous ablation and liver-directed arterial treatments are the most commonly used approaches in BCLM.\u003c\/p\u003e\n\n\u003ch2 id=\"liver-ablation\"\u003ePercutaneous Ablation for Liver Metastases\u003c\/h2\u003e\n\u003cp\u003eRadiofrequency ablation (RFA) and microwave ablation (MWA) are the most common ablation techniques used in clinical practice for treating liver metastases. They can be performed percutaneously (through the skin), laparoscopically (through small keyhole incisions), or during open surgery. The image-guided percutaneous approach — most commonly using ultrasound and CT — is the preferred method for BCLM, where laparoscopy and open surgery are considered unacceptably invasive.\u003c\/p\u003e\n\u003cp\u003eWhile clinical indications for liver ablation in BCLM are still not well-defined, the technical indications are well-established and relate mainly to:\u003c\/p\u003e\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003eTumor size\u003c\/strong\u003e — acceptable size criteria range from 3 to 5 cm in largest diameter, depending on the technique and device used\u003c\/li\u003e\n  \u003cli\u003e\u003cstrong\u003eTumor shape\u003c\/strong\u003e\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eTumor site\u003c\/strong\u003e — location within the liver matters for safe probe placement\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eIt is well-known that local recurrence and treatment failure are higher with larger lesions, due to incomplete ablation at the periphery of the tumor. Therefore, achieving an adequate margin of healthy tissue around the tumor is critical.\u003c\/p\u003e\n\u003cp\u003eOnly a few retrospective studies are available on percutaneous thermal ablation of BCLM, but the results are encouraging:\u003c\/p\u003e\n\u003cul\u003e\n  \u003cli\u003eLocal success with up to \u003cstrong\u003e92% of tumor necrosis\u003c\/strong\u003e (cell death) was reported with RFA ablation — though in that series, up to \u003cstrong\u003e58% of patients\u003c\/strong\u003e developed new liver metastases during follow-up, highlighting the systemic nature of the disease.\u003c\/li\u003e\n  \u003cli\u003eA local tumor progression rate of \u003cstrong\u003e11.6%\u003c\/strong\u003e was reported in a study of \u003cstrong\u003e69 patients with 135 lesions\u003c\/strong\u003e.\u003c\/li\u003e\n  \u003cli\u003eAnother study reported a median overall survival of \u003cstrong\u003e26 months\u003c\/strong\u003e after RFA, with 1-year, 3-year, and 5-year survival rates of \u003cstrong\u003e81.8%, 25.3%, and 11.0%\u003c\/strong\u003e, respectively.\u003c\/li\u003e\n  \u003cli\u003eA recent study of percutaneous RFA for \u003cstrong\u003e64 liver lesions up to 8.5 cm\u003c\/strong\u003e in \u003cstrong\u003e26 drug-resistant patients\u003c\/strong\u003e reported a complete local response rate of \u003cstrong\u003e92.2%\u003c\/strong\u003e and an estimated overall survival of \u003cstrong\u003e29.3 months\u003c\/strong\u003e.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eThese results compare favorably with surgical series, where complete resection of liver metastases is achieved in 62–96% of cases, but with overall mortality rates of up to 5.8%. By comparison, mortality after percutaneous RFA of liver tumors is just \u003cstrong\u003e0.15%\u003c\/strong\u003e. This dramatic difference in safety profile makes percutaneous ablation an appealing option, especially for patients who are not good surgical candidates.\u003c\/p\u003e\n\n\u003ch2 id=\"intra-arterial\"\u003eIntra-Arterial Therapies: Delivering Treatment Through the Blood Supply\u003c\/h2\u003e\n\u003cp\u003eIndications for intra-arterial (IA) therapies are usually less restrictive than for percutaneous ablation, and the aim is more often local tumor control rather than radical (curative) treatment. Patients with BCLM who are considered for IA therapies are typically in a more advanced stage, often with extrahepatic disease and having already received multiple lines of chemotherapy. They frequently have long clinical histories, significant treatment side effects, and may be mentally and emotionally distressed.\u003c\/p\u003e\n\u003cp\u003eThe rationale behind arterial treatment is anatomical: liver tumors — both primary and metastatic — are supplied mainly, if not exclusively, by arterial blood flow. This means that by delivering treatment directly through the hepatic artery, it is possible to achieve higher local concentrations of chemotherapy within the liver metastases while exposing the rest of the body to less of the drug, compared with systemic therapy.\u003c\/p\u003e\n\u003cp\u003eCytotoxic drugs can be delivered in two main ways:\u003c\/p\u003e\n\u003col\u003e\n  \u003cli\u003e\n\u003cstrong\u003eSelective intra-arterial chemotherapy infusion\u003c\/strong\u003e — drugs are infused directly into the artery feeding the tumor\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eChemoembolization\u003c\/strong\u003e — drugs are injected along with embolic agents that slow down the arterial flow, increasing the contact time between the chemotherapy and the cancer cells\u003c\/li\u003e\n\u003c\/ol\u003e\n\u003cp\u003eThe arterial route is also used for radioembolization, which takes advantage of the fact that breast cancer cells are sensitive to radiation.\u003c\/p\u003e\n\u003cp\u003eUnlike thermal ablation, liver-directed intra-arterial therapies are not limited by tumor size. The main indications are usually local tumor control in patients with:\u003c\/p\u003e\n\u003cul\u003e\n  \u003cli\u003eUnresectable liver-only metastases (tumors that cannot be surgically removed)\u003c\/li\u003e\n  \u003cli\u003eBCLM with extrahepatic disease\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eThe main contraindications include:\u003c\/p\u003e\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003eLarge tumor burden\u003c\/strong\u003e — more than 50% of the liver involved by tumor\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eLiver failure\u003c\/strong\u003e — the liver is not functioning adequately\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch2 id=\"tace\"\u003eTransarterial Chemoembolization (TACE)\u003c\/h2\u003e\n\u003cp\u003eTransarterial chemoembolization (TACE) combines local chemotherapy delivery with blockage of the blood supply to the tumor. Mitomycin C and gemcitabine are the most common chemotherapy drugs reported in the literature for this purpose, with no clear evidence that one is superior to the other in terms of effectiveness.\u003c\/p\u003e\n\u003cp\u003eThe role of TACE in unresectable BCLM has been evaluated in a few retrospective studies based on small patient groups. The results show meaningful benefits for patients who respond to treatment:\u003c\/p\u003e\n\u003cul\u003e\n  \u003cli\u003eA median overall survival of \u003cstrong\u003e24 months\u003c\/strong\u003e was reported in responder patients, who received a median of \u003cstrong\u003e4 sessions\u003c\/strong\u003e of TACE\u003c\/li\u003e\n  \u003cli\u003eThis compares with a median survival of only \u003cstrong\u003e7 months\u003c\/strong\u003e in non-responders — a striking difference that underscores the importance of patient selection\u003c\/li\u003e\n  \u003cli\u003eA prospective phase II study evaluated gemcitabine-based TACE in \u003cstrong\u003e43 patients\u003c\/strong\u003e with inoperable BCLM and reported an estimated median overall survival of \u003cstrong\u003e10.2 months\u003c\/strong\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003ePost-embolization syndrome (PES) is the most common side effect after TACE. It typically includes symptoms such as fever, nausea, vomiting, and abdominal pain. The severity of PES is related to the amount of liver tissue treated during the procedure — the more liver parenchyma (functional liver tissue) that is involved, the more pronounced the symptoms tend to be.\u003c\/p\u003e\n\n\u003ch2 id=\"tare\"\u003eTransarterial Radioembolization (TARE)\u003c\/h2\u003e\n\u003cp\u003eRadiation-based tumor treatment has a well-established rationale: radiation has a tumoricidal (tumor-killing) effect, and this effect does not depend on whether the tumor is sensitive to chemotherapy. For breast cancer, this is particularly relevant since breast cancer cells are known to be sensitive to radiation.\u003c\/p\u003e\n\u003cp\u003eTransarterial radioembolization (TARE) was initially developed as a liver-directed therapy for primary liver cancer and colorectal liver metastases. The treatment uses microscopic spheres (microspheres) loaded with yttrium-90 (90Y), a radioactive isotope that emits beta radiation. These microspheres are administered directly into the arterial blood supply of the liver tumors.\u003c\/p\u003e\n\u003cp\u003eSelective administration of the radioactive beads is essential for achieving good oncological results while protecting healthy liver tissue. By delivering radiation directly into the tumor's blood supply, TARE can deliver a high radiation dose to the cancer while sparing the rest of the body.\u003c\/p\u003e\n\u003cp\u003eWhile the review notes that TARE has been less extensively studied in breast cancer liver metastases specifically, the biological rationale is sound: because breast cancer is radiosensitive, liver tumors from breast cancer should respond to targeted radiation delivery through this approach.\u003c\/p\u003e\n\n\u003ch2 id=\"clinical-implications\"\u003eClinical Implications: What This Means for Patients\u003c\/h2\u003e\n\u003cp\u003eThis review has several important messages for patients facing breast cancer treatment decisions.\u003c\/p\u003e\n\u003cp\u003eFirst, if you have early-stage breast cancer and cannot undergo surgery — whether due to other health problems, advanced age, or personal choice — interventional oncology techniques offer viable alternatives. Cryoablation, in particular, has demonstrated an 85% complete ablation rate for tumors up to 2 cm, with the fewest complications among thermal ablation methods and excellent cosmetic results. Ongoing clinical trials like ICE3 and FROST are working to confirm these benefits in larger patient populations.\u003c\/p\u003e\n\u003cp\u003eSecond, if you have breast cancer that has spread to the liver, local treatments can play an important role in specific situations. For patients with only a few liver metastases (five or fewer), percutaneous ablation can achieve local control with a very low risk of serious complications — mortality of just 0.15% compared with up to 5.8% for surgical resection. For patients with more extensive liver involvement, intra-arterial therapies like TACE and TARE can provide meaningful survival benefits, particularly for those who respond to treatment.\u003c\/p\u003e\n\u003cp\u003eThird, the concept of \"oligo-progressive\" disease is a promising development. If you are on a systemic therapy that is working well overall, but one or two liver lesions are growing, local treatment of those specific lesions might allow you to stay on your effective systemic therapy longer, rather than switching to a new treatment.\u003c\/p\u003e\n\u003cp\u003eHowever, the review emphasizes that patient selection is everything. The benefits of these local treatments are most pronounced in well-selected patients, and the decision should always be made within a multidisciplinary team board (MDTB) that includes medical oncologists, surgeons, radiologists, and interventional oncology specialists.\u003c\/p\u003e\n\n\u003ch2 id=\"limitations\"\u003eLimitations: What the Research Can't Yet Tell Us\u003c\/h2\u003e\n\u003cp\u003eIt is essential to understand the limitations of the evidence supporting interventional oncology in breast cancer. This review is honest about these gaps:\u003c\/p\u003e\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003eNo high-level evidence\u003c\/strong\u003e — There are no large randomized controlled trials confirming the effectiveness of local therapies in metastatic breast cancer. Most data come from retrospective studies with small patient cohorts.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eNo specific guidelines\u003c\/strong\u003e — Unlike surgery or systemic therapy, there are no formal clinical guidelines establishing when interventional oncology procedures should be used in breast cancer patients.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eNo histological confirmation\u003c\/strong\u003e — Percutaneous ablation destroys the tumor in place, so it cannot be examined under a microscope to confirm complete removal. This is why a 5 mm safety margin is needed, and why imaging follow-up is critical.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eVariable results across techniques\u003c\/strong\u003e — For HIFU, for example, complete ablation success rates ranged from 20% to 100% in published studies, reflecting differences in equipment, protocols, and patient selection.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eMixed imaging reliability\u003c\/strong\u003e — MRI after laser ablation showed a 92.2% negative predictive value overall, but this was not perfect; 6.7% of patients had false negatives, meaning MRI missed residual disease.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eHigher failure with larger tumors\u003c\/strong\u003e — Local recurrence and treatment failure rates are higher for larger lesions due to incomplete ablation at the periphery.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eOngoing risk of new metastases\u003c\/strong\u003e — Even after successful ablation, many patients develop new liver lesions elsewhere, reflecting the systemic nature of metastatic breast cancer.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eThese limitations are not reasons to avoid these treatments, but they are reasons to approach them with appropriate expectations and to ensure that decisions are made collaboratively with a fully informed care team.\u003c\/p\u003e\n\n\u003ch2 id=\"recommendations\"\u003eRecommendations for Patients\u003c\/h2\u003e\n\u003cp\u003eBased on the findings of this review, here are practical steps patients can consider when discussing interventional oncology options with their care team:\u003c\/p\u003e\n\u003col\u003e\n  \u003cli\u003e\n\u003cstrong\u003eAsk about a multidisciplinary team board (MDTB) discussion.\u003c\/strong\u003e The European School of Oncology recommends that every metastatic breast cancer patient have a tailored treatment plan developed by a multidisciplinary team. Ask your oncologist whether your case has been or will be discussed at an MDTB meeting.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eInquire about interventional oncology expertise.\u003c\/strong\u003e A breast cancer treatment center should have access to interventional radiology specialists. If your center does not, ask for a referral.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eIf you have small, early-stage breast cancer and surgery is not an option for you\u003c\/strong\u003e, ask your doctor whether cryoablation or another thermal ablation technique could be appropriate. Current data show an 85% success rate for tumors up to 2 cm, with a very low complication profile.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eIf you have liver metastases from breast cancer\u003c\/strong\u003e, ask whether local treatments like percutaneous ablation, TACE, or TARE should be considered in addition to your systemic therapy. This is especially relevant if you have only a few liver lesions (≤5, known as oligo-metastatic disease) or if you have one or a few lesions that are growing while your overall disease is otherwise well controlled (oligo-progressive disease).\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eConsider clinical trials.\u003c\/strong\u003e Ongoing studies like ICE3 and FROST are evaluating the role of cryoablation without surgery in early-stage breast cancer. Enrolling in a clinical trial can give you access to cutting-edge treatments while contributing to medical knowledge.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eUnderstand the follow-up requirements.\u003c\/strong\u003e Because ablated tumors are not removed for examination, imaging follow-up (ultrasound, MRI, or CT) is essential after these procedures. Make sure you understand the follow-up schedule and adhere to it.\u003c\/li\u003e\n\u003c\/ol\u003e\n\u003cp\u003e\u003cstrong\u003eImportant note:\u003c\/strong\u003e Every patient's situation is unique. Interventional oncology procedures are not appropriate for everyone, and the decision to pursue them should always be made in close consultation with your entire medical team, taking into account your specific cancer type, stage, overall health, and personal preferences.\u003c\/p\u003e\n\n\u003c!-- ddn:faq:start --\u003e\n\u003ch2 id=\"ddn-faq\"\u003eFrequently Asked Questions\u003c\/h2\u003e\n\u003ch3\u003eI have early-stage breast cancer but cannot have surgery. What minimally invasive options might be available?\u003c\/h3\u003e\n\u003cp\u003eIf surgery is not possible due to other health conditions, advanced age, or personal choice, percutaneous ablation may be considered. Techniques include cryoablation, radiofrequency ablation, microwave ablation, laser ablation, and high-intensity focused ultrasound. These are outpatient procedures with low complication rates, minimal scarring, and rapid recovery. A multidisciplinary team discussion is needed to decide if one is appropriate for you.\u003c\/p\u003e\n\u003ch3\u003eWhat is cryoablation and how successful is it for small breast tumors?\u003c\/h3\u003e\n\u003cp\u003eCryoablation uses extreme cold to destroy cancer cells. A small probe is placed into the tumor under ultrasound guidance, and the ice ball is visible in real time. A meta-analysis of 397 breast cancers up to 2 cm found complete ablation in 339 cases, an 85% success rate. It is essentially painless, needs only local anesthesia, and has the fewest complications among thermal ablation methods.\u003c\/p\u003e\n\u003ch3\u003eWhat are the risks or side effects of thermal ablation for breast cancer?\u003c\/h3\u003e\n\u003cp\u003eHeat-based techniques can be painful and usually require local anesthesia plus intravenous sedation. In one randomized trial, radiofrequency ablation before lumpectomy had a higher complication rate, mainly local breast inflammation and infection, especially when combined with partial breast irradiation. Microwave ablation under general anesthesia caused thermal injuries to skin and chest muscle in some cases. Cryoablation has the fewest complications among thermal ablation methods.\u003c\/p\u003e\n\u003ch3\u003eIf I have breast cancer that has spread to the liver, can ablation or other local treatments help?\u003c\/h3\u003e\n\u003cp\u003eFor a limited number of liver metastases (five or fewer), percutaneous ablation can achieve local control with a very low risk of serious complications. Mortality after percutaneous radiofrequency ablation of liver tumors is 0.15%, compared with up to 5.8% for surgical resection. For more extensive liver involvement, intra-arterial therapies like TACE or TARE may provide survival benefits, especially in patients who respond to treatment.\u003c\/p\u003e\n\u003ch3\u003eWhat does it mean if I have 'oligo-progressive' disease?\u003c\/h3\u003e\n\u003cp\u003eOligo-progressive disease means that while your systemic therapy is working well overall, one or a few liver lesions are growing. Instead of switching the systemic treatment, which may still be effective elsewhere, treating only those non-responsive lesions locally might allow you to continue the effective systemic therapy longer. This approach is still being studied and requires discussion within a multidisciplinary team.\u003c\/p\u003e\n\u003ch3\u003eWhy is imaging follow-up needed after ablation instead of examining the tumor?\u003c\/h3\u003e\n\u003cp\u003ePercutaneous ablation destroys the tumor in place, so it cannot be removed and examined under a microscope to confirm complete removal. Doctors therefore oversize the ablation area, aiming for a 5 mm margin beyond the visible tumor. Imaging follow-up with ultrasound, MRI, or CT is essential to check for any residual or recurrent disease. Make sure you understand and adhere to the follow-up schedule.\u003c\/p\u003e\n\u003ch3\u003eAre there clinical trials testing cryoablation without surgery for early breast cancer?\u003c\/h3\u003e\n\u003cp\u003eYes. The ICE3 trial is studying cryoablation in women aged 50 or over with early-stage hormone receptor-positive, HER2-negative breast cancer. Its interim analysis reported an ipsilateral breast tumor recurrence rate of only 2% at a mean follow-up of 34.83 months. The FROST trial is evaluating cryoablation without surgery and its impact on local or distant recurrence at 5 years. Enrolling in a trial can give access to treatments under study.\u003c\/p\u003e\n\u003ch3\u003eIf I have early-stage breast cancer and cannot have surgery, or breast cancer that has spread to the liver, when should I seek a second opinion?\u003c\/h3\u003e\n\u003cp\u003eSeek a second opinion when surgery is not possible for early-stage disease due to comorbidities, advanced age, or personal choice, and you want to know whether cryoablation or another thermal ablation technique is appropriate; cryoablation achieved complete ablation in 85% of tumors up to 2 cm. Also seek one if breast cancer has spread to the liver and you have five or fewer lesions, or one or a few lesions growing while systemic therapy otherwise works, to review percutaneous ablation, TACE, or TARE. Diagnostic Detectives Network provides independent expert second opinions.\u003c\/p\u003e\n\u003c!-- ddn:faq:end --\u003e\n\n\u003ch2 id=\"source\"\u003eSource Information\u003c\/h2\u003e\n\u003cp\u003eThis patient-friendly article is based on peer-reviewed research.\u003c\/p\u003e\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003eOriginal article title:\u003c\/strong\u003e J Med Imag Rad Onc - 2023 - Orsi - Interventional oncology in breast cancer\u003c\/li\u003e\n\u003c\/ul\u003e","brand":"DiagnosticDetectives.Com","offers":[{"title":"Default Title","offer_id":47699389218972,"sku":null,"price":0.0,"currency_code":"KRW","in_stock":true}],"url":"https:\/\/diagnosticdetectives.kr\/products\/interventional-oncology-for-breast-cancer-a-patients-guide-to-minimally-invasive-treatments","provider":"DiagnosticDetectives.Com","version":"1.0","type":"link"}